InvestSMART

Tissue Repair Ltd (ASX:TRP)

ALERT: Price-sensitive ASX Announcement for TRP
Current share price for TRP : $0.085 0.002 (2.41%)+
Announcement
Release
31 Jul 2026 9:28AM
Price at Release
$0.083
Full Release
download
Summary
Tissue Repair Limited (ASX: TRP) has released its Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 June 2026. The company reported a net operating cash outflow of $1.848 million, driven by expenditures in research and development, manufacturing, and operating costs. The cash balance at the end of the quarter was $4.759 million, bolstered by an R&D tax incentive refund of $1.9 million received on 1 July 2026. The company is advancing its US Phase III clinical trial for TR-987 for chronic wounds, with approximately 100 patients randomized and plans for an FDA 510(k) submission in October 2026. Additionally, TR Pro+ is set for commercial launch in Australia with GMP production completed. The company is positioned to expand into the global acute wound market, and recent regulatory reimbursement changes have enhanced the commercial prospects of its products.
Key Points
  • US Phase III clinical trial for TR-987 progressing with 100 patients randomized.
  • Planned FDA 510(k) submission in October 2026.
  • Cash balance at 30 June 2026 was $4.759 million.
  • Received a $1.9 million R&D tax refund on 1 July 2026.
  • Net operating cash outflow for the quarter was $1.848 million.
  • TR Pro+ commercial launch in Australia with GMP production completed.
  • Favorable US reimbursement framework established post-regulatory changes.
  • Estimated R&D tax incentive refund for FY26 is $2.2 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.